Overall rank 251 · Score 89 · 2020 Nov
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.
American heart journal
Clinical trialAI-recommended Tier BWeight loss & obesityCardiovascularHeart failureSafety
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 252 · Score 86 · 2017 Nov
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.
Clinical pharmacokinetics
Clinical trialAI-recommended Tier BKidneyPediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains clinical trial evidence with a Tier B recommendation. No experimental retesting was performed or required.
Overall rank 253 · Score 80 · 2025 Apr
Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.
Diabetes, obesity & metabolism
ObservationalAI-recommended Tier CWeight loss & obesitySafetyOphthalmicDiscontinuation & regainReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 254 · Score 80 · 2025 Oct 14
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.
JAMA
ObservationalAI-recommended Tier CWeight loss & obesityCardiovascularHeart failureSafetyReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 255 · Score 80 · 2025 Nov
Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World).
Diabetes, obesity & metabolism
ObservationalAI-recommended Tier CCardiovascularKidneyHeart failureSafetyReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 256 · Score 80 · 2025 Apr 24
Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes.
Cardiovascular diabetology
ObservationalAI-recommended Tier CType 2 diabetesCardiovascularKidneyReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 257 · Score 80 · 2025 Jul
Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence.
Annals of the American Thoracic Society
ObservationalAI-recommended Tier CCardiovascularSafetyReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 258 · Score 80 · 2025 Nov
Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic.
Diabetes, obesity & metabolism
ObservationalAI-recommended Tier CWeight loss & obesityReal-world evidencePediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 259 · Score 80 · 2026 Mar
Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER).
Diabetes, obesity & metabolism
ObservationalAI-recommended Tier CHeart failureDiscontinuation & regain
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 260 · Score 80 · 2026 Jun 22
Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.
The British journal of ophthalmology
ObservationalAI-recommended Tier COphthalmicReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 261 · Score 80 · 2025 Mar
Ocular adverse events associated with GLP-1 receptor agonists: a real-world study based on the FAERS database and network pharmacology.
Expert opinion on drug safety
ObservationalAI-recommended Tier COphthalmicReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 262 · Score 80 · 2025 Jan 1
Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder.
JAMA psychiatry
ObservationalAI-recommended Tier CReal-world evidencePediatric & adolescent
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 263 · Score 80 · 2025 Apr 1
Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy.
JAMA ophthalmology
ObservationalAI-recommended Tier COphthalmicReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 264 · Score 80 · 2025 Jun
Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study.
Diabetes, obesity & metabolism
ObservationalAI-recommended Tier COphthalmicReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 265 · Score 80 · 2025 Apr 28
Association between various dosage forms of semaglutide and ocular adverse events in a real-world setting.
BMC ophthalmology
ObservationalAI-recommended Tier COphthalmicReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 266 · Score 80 · 2025 Sep
Association of Glucagon-Like Peptide-1 Receptor Agonists With Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries.
American journal of ophthalmology
ObservationalAI-recommended Tier COphthalmicReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 267 · Score 80 · 2025 Jul
Comparison of Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes : Two Target Trial Emulation Studies.
Annals of internal medicine
ObservationalAI-recommended Tier CCardiovascularReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 268 · Score 80 · 2025 Sep 12
Semaglutide and Tirzepatide in a Remote Weight Management Program: 12-Month Retrospective Observational Study.
JMIR formative research
ObservationalAI-recommended Tier CWeight loss & obesityReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 269 · Score 80 · 2026 Jan 6
Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study.
The British journal of dermatology
ObservationalAI-recommended Tier CReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 270 · Score 80 · 2026 Jan
Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.
Diabetes, obesity & metabolism
ObservationalAI-recommended Tier CType 2 diabetes
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 271 · Score 80 · 2026 Mar
Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes.
Diabetes, obesity & metabolism
ObservationalAI-recommended Tier CHeart failure
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 272 · Score 80 · 2026 May
Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study.
Diabetes research and clinical practice
ObservationalAI-recommended Tier CReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 273 · Score 80 · 2026 May
Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study.
Journal of diabetes and its complications
ObservationalAI-recommended Tier CReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 274 · Score 80 · 2026 Aug
Real-World Effectiveness and 12-Month Persistence of a Semaglutide-Supported Digital Weight-Loss Service: A Retrospective Cohort Study in Germany.
Diabetes, obesity & metabolism
ObservationalAI-recommended Tier CReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Overall rank 275 · Score 80 · 2026 Aug
Real-World Effectiveness of Semaglutide and Tirzepatide Compared With Bariatric Surgery.
Obesity (Silver Spring, Md.)
ObservationalAI-recommended Tier CReal-world evidence
AI appraisal complete: source relevance and evidence-class signals checked from PubMed title/abstract, publication types, and registry metadata. The record remains observational evidence with a Tier C recommendation. No experimental retesting was performed or required.
Source registry generated 2026-09-17; AI appraisal completed 2026-09-22 under WPF-SGLT-AI-APPRAISAL-1.0. Humans resolve only the three displayed exceptions and record one accountable bundle publication decision. Records can appear in multiple domains; domain totals therefore overlap.